Displaying 241 - 243 of 243
Alternative Name: Miglustat; N-butyldeoxynojirimycin (NB-DNJ)
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Oral
Developer: University of Washington, Oxford GlycoSciences
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: University of Nairobi
Development Stage: Lead Optimization
Development Phase: Discovery and Early Development
Alternative Name: β-human chorionic gonadotropin
User: Female
Hormonal: No
Duration Type: Short-acting
Developer: Talwar Research Foundation, Indian Council for Medical Research
Development Stage: Phase II
Development Phase: Pre-Clinical and Clinical Development

Pages

Displaying 51 - 60 of 70
User: Female
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Innolytics LLC
Development Stage: Lead Optimization
PC6
Alternative Name: Proprotein convertase 6
Target
Hormonal: No
Developer: CONRAD, Prince Henry's Institute of Medical Research, Australia
Development Stage: Target Validation
Alternative Name: Phosphodiesterase 3, 5, 9, PDE3A
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, University of Minnesota
Development Stage: Target Identification
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Vaginal Gel, Vaginal Ring
Developer: Ottawa Hospital Research Institute (OHRI)
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Vindico NanoBio Technology Inc.
Development Stage: Lead Optimization
Alternative Name: PGE2
Target
User: Female
Hormonal: No
Developer: Oregon Health & Science University, Bayer HealthCare
Development Stage: Target Identification
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel, Other
Development Stage: Compound ID/Selection
Alternative Name: Retinoic acid receptor (RAR) antagonists
Target
User: Male
Hormonal: No
Duration Type: Short-acting
Developer: NICHD, Columbia University, University of Washington, University of Minnesota
Development Stage: Target Validation
Alternative Name: l-CDB-4022
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Development Stage: Lead Optimization
Alternative Name: Serum- and Glucocorticoid-Regulated Kinase
Target
User: Female
Hormonal: No
Developer: CONRAD, Imperial College, London
Development Stage: Target Identification

Pages

Displaying 41 - 50 of 121
User: Male
Hormonal: No
Duration Type: Permanent, Short-acting
Delivery Method: Oral
Developer: WHO, South-to-South Cooperation in Reproductive Health
Development Stage: Phase I
Alternative Name: SARM C-6
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: GTx, Inc., Memphis, TN
Development Stage: Pre-clinical
Alternative Name: H2-GMZ
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: University of Kansas Medical Center, University of Minnesota
Development Stage: Pre-clinical
Alternative Name: Injectable Gestodene (GES) + Ethinyl Estradiol (EE)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Peking University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Stanford University
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: University of California San Diego
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: KYDES Pharmaceuticals, FHI 360
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: University of Tennessee Health Sciences Center
Development Stage: Pre-clinical
Alternative Name: Gendarussa
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Oral
Developer: Airlangga University, Indopharma, FHI 360
Development Stage: Phase II
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: ContraMed, LLC
Development Stage: Phase II

Pages

Displaying 1 - 10 of 52
Alternative Name: Smaller/Nulliparous Copper IUD, Liberté TT380 Short, Micro T
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: 7Med Industrie, France
Development Stage: SRA/WHO PQ Approved
Alternative Name: Nestorone + Ethinyl Estradiol One-Year Contraceptive Vaginal Ring, NES + EE Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Vaginal Ring
Developer: Population Council, NICHD, WHO, USAID, NIH, Bill & Melinda Gates Foundation, Avis and Clifford Barrus Medical Foundation
Development Stage: SRA/WHO PQ Approved
Alternative Name: SILCS Diaphragm
User: Female
Hormonal: No
Duration Type: Short-acting, Pericoital
Delivery Method: Barrier
Developer: PATH, CONRAD, SILCS, Inc., Kessel Marketing & Vertriebs GmbH
Development Stage: SRA/WHO PQ Approved
Alternative Name: Saheli; Ormeloxifene
User: Female
Hormonal: No
Duration Type: Short-acting, Emergency
Delivery Method: Oral
Developer: Central Drug Research Institute, India, HLL Lifecare Limited
Development Stage: Marketed
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Chongqing Medical Equipment Factory Co., Ltd.
Development Stage: Marketed
Alternative Name: Nanocomposite Copper (Cu) IUD
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Tongji Medical College at Huazhong University of Science and Technology
Development Stage: Marketed
Alternative Name: l'Amour®; Jeitosa®
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Cupid Ltd.
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Concept Foundation, Sun Pharmaceuticals, India, WHO HRP, PT. Tunggal Idaman Abdi
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: DKT International, PT Harsen
Development Stage: Marketed

Pages

CSV